(Y50) Central nervous system stimulants, not elsewhere classified

More details coming soon

Icon
6 670 in individuals diagnosis central nervous system stimulants, not elsewhere classified confirmed

Diagnosis central nervous system stimulants, not elsewhere classified is diagnosed Men are 1.83% more likely than Women

3 396

Men receive the diagnosis central nervous system stimulants, not elsewhere classified

0 (less than 0.1%)

Died from this diagnosis.

100
95
90
85
80
75
70
65
60
55
50
45
40
35
30
25
20
15
10
5
0
3 274

Women receive the diagnosis central nervous system stimulants, not elsewhere classified

0 (less than 0.1%)

Died from this diagnosis.

Risk Group for the Disease central nervous system stimulants, not elsewhere classified - Men aged 15-19 and Women aged 10-14

Icon
In Men diagnosis is most often set at age 15-19, 25-29, 80-84
Icon
Less common in men the disease occurs at Age 0-14, 20-24, 30-79, 85-95+Less common in women the disease occurs at Age 0-5, 15-95+
Icon
In Women diagnosis is most often set at age 0-1, 5-14

Disease Features central nervous system stimulants, not elsewhere classified

Icon
Absence or low individual and public risk
Icon

Central nervous system stimulants, not elsewhere classified - what does this mean

Central nervous system stimulants, not elsewhere classified, are drugs that act on the brain and nervous system to produce an increase in alertness, energy, and focus, but can also cause side effects such as anxiety, restlessness, and insomnia. these drugs work by increasing the activity of certain neurotransmitters, such as dopamine and noradrenaline, which can lead to an increase in heart rate, blood pressure, and respiration.

What happens during the disease - central nervous system stimulants, not elsewhere classified

Central nervous system stimulants, not elsewhere classified, stimulate the brain and other parts of the nervous system, leading to increased alertness, energy, and euphoria. however, long-term use of these drugs can cause increased anxiety, paranoia, and insomnia, as well as physical effects such as increased heart rate and blood pressure. in the long term, these drugs can also cause damage to the brain and other parts of the nervous system, leading to memory loss, confusion, and other cognitive deficits.

Clinical Pattern

More details coming soon

How does a doctor diagnose

  • Physical examination
  • Neurological examination
  • Blood tests
  • Imaging tests
  • Urine tests
  • Electroencephalogram (EEG)
  • Magnetic resonance imaging (MRI)
  • Computerized tomography (CT) scan
  • Positron emission tomography (PET) scan

Treatment and Medical Assistance

Main Goal: Treating the Disease Central Nervous System Stimulants, Not Elsewhere Classified
  • Prescribing medication to increase alertness and attention.
  • Providing lifestyle advice for better sleep and diet.
  • Recommending physical activity and mental stimulation.
  • Developing strategies to manage stress and anxiety.
  • Encouraging relaxation techniques such as yoga and meditation.
  • Referring to psychotherapy or counselling.
  • Administering cognitive-behavioral therapy.
  • Prescribing antidepressants or anti-anxiety medications.
  • Recommending dietary supplements and vitamins.
  • Administering electroconvulsive therapy.
Icon
3 Days of Hospitalization Required
Icon
Average Time for Outpatient Care Not Established

Central nervous system stimulants, not elsewhere classified - Prevention

The primary prevention of central nervous system stimulants, not elsewhere classified is through education and awareness. this includes educating people on the risks associated with the use of these drugs, as well as the potential consequences of misuse. additionally, healthcare providers should be encouraged to provide information on the risks associated with these drugs, and to provide resources and support to those who may be at risk for developing an addiction.

Specified forms of the disease

(Y50.0) Analeptics
(Y50.1) Opioid receptor antagonists
(Y50.2) Methylxanthines, not elsewhere classified
(Y50.8) Other central nervous system stimulants
(Y50.9) Central nervous system stimulant, unspecified